Get the Stockscreener App
130.65
1.25%
-1.66
Biogen Inc stock is traded at $130.65, with a volume of 1.21M.
It is down -1.25% in the last 24 hours and up +6.08% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$132.31
Open:
$130.87
24h Volume:
1.21M
Relative Volume:
0.73
Market Cap:
$19.51B
Revenue:
$9.82B
Net Income/Loss:
$1.48B
P/E Ratio:
12.90
EPS:
10.13
Net Cash Flow:
$2.30B
1W Performance:
-1.86%
1M Performance:
+6.08%
6M Performance:
-12.92%
1Y Performance:
-44.13%
1-Day Range:
$130.10
$132.49
1-Week Range:
$130.10
$136.84
52-Week Range:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
130.65 | 19.51B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
819.36 | 691.15B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
157.10 | 373.01B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
191.08 | 335.32B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVO
Novo Nordisk Adr
|
79.83 | 331.61B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
119.45 | 233.10B | 53.22B | 12.86B | 14.85B | 6.39 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
NorthCrest Asset Manangement LLC Buys 2,126 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com
Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum
Biogen Requests to Dismiss Class Action Filed by Investors - TradingView
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus
Biogen's (BIIB) Neutral Rating Reaffirmed at Piper Sandler - MarketBeat
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results - Benzinga
Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat
Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus
Biogen: positive Phase 3 data in lupus - marketscreener.com
Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat
Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga
Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com
Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus
Is Biogen Stock Underperforming The S&P 500? - Barchart.com
Is Biogen Stock Underperforming the S&P 500? - The Globe and Mail
Biogen outlines Phase III ambitions for felzartamab in pipeline push - The Pharma Letter
Biogen (BIIB) Shows Promise in Lupus Treatment Study | BIIB Stoc - GuruFocus
Biogen (BIIB) Shows Promise in Lupus Treatment Study | BIIB Stock News - GuruFocus
Biogen, UCB Say Dapirolizumab Pegol Phase 3 Study Shows Improvement in Fatigue, Reduction in Disease Activity - marketscreener.com
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual - GuruFocus
Merit Financial Group LLC Has $1.23 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity - Biogen
Breakthrough Lupus Treatment: New Phase 3 Data Shows Dapirolizumab Doubles Disease Control Rate - Stock Titan
Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases - insights.citeline.com
Transcript : Biogen Inc.Special Call - marketscreener.com
Düsseldorf Higher Regional Court overturns ruling on Biogen’s Imraldi - JUVE Patent
Biogen (BIIB) Explores New Frontiers with Felzartamab in Kidney Disease | BIIB Stock News - GuruFocus
Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases - Biogen
BIIB COURT DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Legal Deadline - ACCESS Newswire
Ill. Judge Questions Standing In Biogen Antitrust Suit - Law360
Biogen at Goldman Sachs Conference: Strategic Shifts and Pipeline Progress - Investing.com Australia
Transcript : Biogen Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - marketscreener.com
Chinese Firm Halts Production of Controversial Alzheimer’s Drug - Bloomberg
Judge To Limit Experts in Biogen, Genentech Drug Royalty Trial - Law360
Recombinant DNA Technology Market Set to Revolutionize - openPR.com
Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class ActionBIIB - ACCESS Newswire
Wealth Enhancement Advisory Services LLC Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
GAMMA Investing LLC Grows Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Czech National Bank Has $4.60 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Rhumbline Advisers Purchases 27,703 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Infographic: Leqembi – A Geographical Comparison - insights.citeline.com
Biogen patents new TYK2 inhibitors - BioWorld MedTech
Former Biogen Chief Medical Officer Joins Candel Board as Prostate Cancer Drug Nears FDA Filing - Stock Titan
Neuralgia Treatment Market Deep Research with Forecast - openPR.com
Biogen Announces Webcast of Annual Meeting of Stockholders - Biogen
July 25th Options Now Available For Biogen (BIIB) - Nasdaq
Neuroprotection Market Booming with Drug Development in CNS Disorders | Biogen, Teva Pharmaceuticals - openPR.com
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):